design, rigorous entry criteria, and comprehensive phenotypic characterization of the RELAX cohort afford a unique opportunity to enhance our understanding of the pathophysiology of HFpEF by evaluating factors associated with exercise capacity in HFpEF. We hypothesized that measures of resting LV diastolic function, myocardial contractility, and vascular function are associated with pVO 2 in HFpEF independently of age, sex, body size, hemoglobin, and chronotropic function.
Methods
The RELAX trial was a multicenter, randomized clinical trial conducted within the National Heart Lung and Blood Institutesponsored HF clinical research network (HFN). The institutional review boards of the participating HFN clinical centers approved the RELAX study and all the subjects provided informed consent prior to participation in the study. The rationale and study design and the primary results of the RELAX trial have been previously published. 13, 14 All participants underwent a baseline cardiopulmonary exercise test (CPXT), a 6 minute walk test, and a two-dimensional and Doppler transthoracic echocardiogram. Cardiac MRI (CMR) without administration of contrast was performed in those without claustrophobia, implantable cardiac device, or body size limitation (body circumference too large to fit in CMR chamber). Those in atrial fibrillation did not undergo CMR because of technical challenges with ECG gating in atrial fibrillation.
The current study evaluated the baseline data obtained prior to randomization. This ancillary study was designed and approved by the HFN ancillary studies committee prior to study completion. All analyses were completed by the HFN data-coordinating center.
Study Subjects
The RELAX trial enrolled 216 ambulatory subjects with HFpEF. Entry criteria specified New York Heart Association (NYHA) class II-IV HF symptoms, LVEF ≥50%, and objective evidence of HF (HF hospitalization, invasively documented elevation in LV filling pressures at rest, left atrial enlargement in the setting of chronic diuretic therapy for HF). Further, at study entry, patients were required to have pVO 2 ≤60% of the age/sex predicted normal value 15 and an elevated (≥400 pg/mL) N-terminal proB type natriuretic peptide, elevated (≥200 pg/mL) B-type natriuretic peptide plasma level, or previously documented elevated LV filling pressures (at rest or with exercise) at the time N-terminal proB type natriuretic peptide or B-type natriuretic peptide was not elevated. 14 
Doppler Echocardiography
Brachial blood pressure and heart rate (HR) were measured while the echocardiogram was being recorded. LV cavity dimension and wall thicknesses were measured from two-dimensional images and used to calculate EF. Reported EF preferentially used biplane Simpson method, modified Quinones formula, single plane volumetric or visual estimate. Endocardial fractional shortening, midwall fiber shortening, and end-systolic wall stress (cESS) were measured as previously described. Contractility was assessed by indexing endocardial fractional shortening (stress corrected) or midwall fiber shortening to log transformed cESS. 16 Stroke volume (SV) was calculated from the time velocity integral of the pulsed wave Doppler signal of LV outflow tract flow and LV outflow tract area. Pulmonary artery systolic pressure was calculated from the peak tricuspid regurgitant velocity and the estimated right atrial pressure using the simplified Bernoulli equation. The early diastolic medial mitral annular tissue velocity (e′) was used as a measure of LV relaxation. The early mitral inflow deceleration time is a frequently reported diastolic function measure which reflects the combined effects of relaxation, LV stiffness, and filling pressures. The ratio of the early transmitral flow velocity (E) to e′ (E/e′) was used as a measure of LV filling pressure. A modification of a previously established ordinal diastolic function grading system was also used. 17 The HFN core echocardiography laboratory (Mayo Clinic, Rochester, MN) completed all measurements according to the American Society of Echocardiography recommendations.
Pulse pressure and mean arterial pressure were calculated using standard formulae. End-systolic pressure was estimated as 0.9×sys-tolic blood pressure. 18 Effective arterial elastance (Ea; end-systolic pressure/SV), total systemic arterial compliance (SAC; SV/pulse pressure), and systemic vascular resistance (SVR; (mean arterial pressure/[cardiac output])×80) were derived as previously described.
18

Cardiac Magnetic Resonance
Brachial blood pressure and HR were measured during the CMR. Aortic distensibility was measured using aortic maximal (CSA max ) and minimal cross sectional area (CSA min ) as (aortic CSA max −aortic CSA min )/(aortic CSA min ×(pulse pressure) (mm Hg -1 ). 4 The HFN core CMR laboratory (Duke University, Durham, NC) performed all CMR measurements.
CPXT and 6 Minute Walk Test
A symptom-limited CPXT was performed on a cycle or treadmill using specifically designed CPXT protocols and analyzed by the HFN core CPXT laboratory (Massachusetts General Hospital, Boston, MA) using established methodologies as previously described.
14 Briefly, this custom CPXT protocol incorporated an initial low work rate with linear increase to yield a linear oxygen uptake during exercise. The protocol consisted of a 5-minute rest period with collection of gas exchange data, followed by a 3-minute period of low and then a 10 W/ min symptom-limited incremental ramp. A cycle ergometer and two treadmill protocols (< or ≥80 kg, to account for the influence of weight on treadmill work rate) were designed to match the workload at a given exercise time.
14 Ventilatory anaerobic threshold was determined by the modified V-slope method. 19 All personnel who performed testing were blinded to treatment allocation of the study subjects.
While published normative values for pVO 2 were used to document exercise limitation for study entry, 15 age, sex, body size, and modalitypredicted pVO 2 was also calculated using the Wasserman equation, and the % predicted VO 2 achieved was calculated. 20 The Wasserman equation estimates predicated pVO 2 based on age, sex, body size, and exercise modality and accounts for the training effect of obesity on pVO 2 in healthy persons allowing a 6 mL/min increase in predicted pVO 2 for each kg of weight compared with ideal body weight.
The age, sex, height-and weight-predicted 6 minute walk distance (6MWD) and % predicted 6MWD were calculated. 21 Age-predicted maximal HR was defined by the formula (220 − age). 22 Chronotropic index defined as the predicted HR reserve achieved during exercise 23 
Results
Clinical Characteristics of the RELAX Participants
Baseline characteristics of the RELAX participants (n=216) have been published previously. 13 Briefly, the median age of , which represented 41% of the age-and sex-predicted normal value 15 and 67% of pVO 2 predicted from the Wasserman equation, 20 whereas median 6MWD was 307 m (67% of predicted). 21 Baseline characteristics of subjects were assessed according to tertiles of pVO 2 (Table 1) , respectively. Patients with lower pVO 2 were older, more likely to be women and more obese (Table 1) . There was no difference in the prevalence of hypertension, coronary artery disease, or chronic obstructive pulmonary disease across the tertiles of pVO 2 . However, atrial fibrillation, diabetes mellitus, renal BMI indicates body mass index; BSA, body surface area; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; ICD, implantable cardioverter defibrillator; JVP, jugular venous pressure; MLWHFQ, Minnesota living with heart failure questionnaire; NT-proBNP, N-terminal proB type natriuretic peptide; NYHA, New York Heart Association; and VO 2 , oxygen consumption. dysfunction (lower eGFR and higher serum creatinine), and anemia (lower hemoglobin) were more common in those with lower pVO 2 .
There was no difference in the frequency of use of β blockers, calcium channel blockers, or digoxin across the tertiles of pVO 2 . However, patients with lower pVO 2 were more likely to be on loop diuretics and required higher doses of diuretics (Table 1) .
Patients with lower pVO 2 had more severe symptoms (NYHA class); however, the Minnesota Living with Heart Failure Questionnaire Total Score was not significantly different across the tertiles of pVO 2 . Patients with lower pVO 2 had evidence of more severe congestion (elevated jugular venous pressure, peripheral edema) and higher N-terminal proB type natriuretic peptide levels ( Table 1) .
Functional Capacity in HFpEF
Patients with lower pVO 2 had lower % predicted pVO 2 (Wasserman equation) and shorter 6MWD (Table 2 ). Peak respiratory exchange ratio was not significantly related to pVO 2 , likely because of a respiratory exchange ratio of ≥1 in most subjects, and the narrow range of respiratory exchange ratio achieved (median 1.09, 1.02-1.15). Subjects with lower pVO 2 exercised for shorter duration and achieved lower HR, chronotropic index, and blood pressure at peak exercise. Patients with lower pVO 2 had lower submaximal exercise capacity (VO 2 at anaerobic threshold, AT).
Relationship of Cardiovascular Structure and Function to Exercise Capacity
Subjects with lower pVO 2 tended to have smaller LV diastolic diameter and had lower LV mass but not LV mass indexed to body size (Table 3) . There was no difference in geometry (relative wall thickness) across the tertiles of pVO 2 .
Neither EF nor other indices of myocardial contractility (stress corrected endocardial fractional shortening or midwall fiber shortening) were different across the tertiles of pVO 2 (Table 3) .
Patients with lower pVO 2 had more severe diastolic dysfunction, evidenced by higher mitral inflow E/A ratio and E/e′ and shorter deceleration time, although e′ was not different across tertiles of pVO 2 . Using an ordinal diastolic dysfunction severity scale, those with lower pVO 2 had more advanced diastolic dysfunction. However, this difference was not statistically significant as the majority of patients enrolled in RELAX had a pseudonormal or restrictive pattern (Table 3) .
Patients with lower pVO 2 had higher pulmonary artery systolic pressure (Table 3) , but there were no differences in systemic vascular function indices across tertiles of pVO 2 (Table 3) . As previously established in normal persons and in persons with cardiovascular disease, 24 age, sex, BMI, hemoglobin, and chronotropic reserve were associated with pVO 2 in HFpEF (Figure 1 ), and these variables explained 64% of the variability in pVO 2 (mL/min) and 49% of weight-indexed pVO 2 in the RELAX study population (Tables 4 and 5 , Table 1 and Table 4 ) but positively associated with nonindexed pVO 2 (mL/min) ( Figure 1 and Table 5 ). The % predicted pVO 2 (Wasserman equation) was not associated with BMI (Figure 2) .
In RELAX, CPXT was performed on a treadmill in 81 (38%) and on a cycle in 134 (62%). Adjusting for these variables, there was no association between exercise modality and pVO 2 . (Table 6 ), whereas relative wall thickness had no association with pVO 2 . SV was positively associated with pVO 2 explaining an additional 2.0% of the variability in pVO 2 in HFpEF patients. There was no association between other resting indices of systolic function and pVO 2 ( Table 6) .
Indexes of diastolic dysfunction (higher e′, E/e′, and shorter deceleration time) were associated with lower pVO 2 with each variable explaining an additional 1% of the variability in pVO 2 in HFpEF. However, the ordinal diastolic dysfunction grade, E/A ratio, and LA volume were not associated with pVO 2 (Table 6 ). Pulmonary artery systolic pressure showed a strong trend toward association with pVO 2 , but this was not statistically significant (P=0.09), Table 6 .
Higher total systemic arterial load (Ea) and lower SAC were each associated with lower pVO 2 explaining an additional 2.1% (Ea) or 1.5% (SAC) of the variability of pVO 2 in HFpEF. SVR and aortic distensibility were not significantly associated with pVO 2 (Table 6 ).
Discussion
In this prospectively identified and rigorously characterized HFpEF cohort, age, sex, body size, hemoglobin, and chronotropic reserve collectively explained 64% of the variability in pVO 2 . After accounting for these variables, LV size and mass, parameters reflecting the severity of diastolic dysfunction and elevated LV filling pressures, SV, and systemic arterial function were each only modestly, albeit significantly associated with pVO 2 . These findings suggest that potentially modifiable factors (obesity, anemia, and chronotropic incompetence) potently contribute to exercise intolerance in HFpEF. The relatively weak or absent association of resting measures of LV systolic, LV diastolic, or vascular function with exercise capacity suggests that the cardiovascular response to exercise is poorly correlated with resting measures in HFpEF.
Exercise Capacity in RELAX
Despite striking differences in ventricular-vascular properties, studies have shown that the degree of exercise intolerance is similar in HFpEF and HFrEF. 2, 3, 25, 26 Notably, pVO 2 in the HFpEF patients enrolled in RELAX was lower than previously described in HFpEF cohorts with NYHA class II/III symptoms, 2, 25, 27, 28 or in HFrEF with LVEF<35% and similar NYHA class. 29 The severity of exercise intolerance as measured by pVO 2 or 6MWD in the RELAX HFpEF cohort 13 not only reflects the demographics of the HFpEF population as elderly persons, women, and obese persons having lower reference ranges for weight-indexed pVO 2 and 6MWD but also reflects the RELAX entry criteria that mandated a pVO 2 ≤60% of predicted for age and sex. 15 In comparison, a recent multicenter trial investigating the effect of spironolactone on exercise capacity in HFpEF used a more liberal entry criteria (pVO 2 ≤25 mLkg −1 min −1 regardless of age and sex) 28 and therefore enrolled a cohort with higher median pVO 2 (16.4 mLkg
), milder symptoms, better diastolic function, and fewer comorbidities than observed in RELAX. These differences in prospectively enrolled HFpEF cohorts underscore the spectrum of debility in HFpEF and confirm the validity of pVO 2 as a marker of disease severity in HFpEF.
Association of Systolic Function With Exercise Capacity in HFpEF
Contrary to our hypothesis and consistent with small studies in HFrEF, 30 neither resting LV chamber (EF and endocardial fractional shortening) nor myocardial (stress corrected midwall fiber shortening) systolic performance were significantly related to exercise capacity in HFpEF although resting SV was.
In a large randomized clinical trial of exercise training in HFrEF, resting EF was positively associated with pVO 2 in HFrEF, 29 but explained only 1% of the variance in pVO 2 .
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The association between resting SV and exercise capacity observed here is consistent with a previous study in HFpEF where resting and peak SV were lower in HFpEF than controls and each associated with pVO 2 . Despite normal EF, patients with HFpEF have subtle reduction in measures of myocardial contractility, 31 blunted increases in EF and SV in response to exercise 7, 9, 32, 33 , and modest but significant reduction in EF over time. Although lower resting SV may identify patients with more limited ability to enhance SV with exercise, this association was not strong with resting SV, explaining only 2% of the variance in pVO 2 .
Association of Diastolic Function With Exercise Capacity in HF
Diastolic function indexes were the most significant correlates of exercise capacity in previous studies in HFrEF, 29, 34 where higher E/A ratio was associated with lower pVO 2 after adjustment for pertinent covariates, explaining an additional 6% of the variance in pVO 2 . 29 In some previous HFpEF studies, the severity of resting diastolic dysfunction assessed with novel indices was associated with more impaired exercise capacity 7 , whereas larger studies did not find an association between resting conventional Doppler diastolic function indices and exercise capacity. 12, 35 In this fairly advanced HFpEF cohort, resting Doppler indices known to be associated with LV diastolic dysfunction and elevation of LV filling pressures were only modestly associated with impairment in pVO 2 after adjustment for pertinent covariates. This may reflect the variability and insensitivity of the diastolic indices to elevation of LV filling pressures. Alternatively, the severity of exercise-induced diastolic dysfunction may be variably related to resting diastolic function. Studies in patients with NYHA class II HF symptoms and normal EF demonstrated marked elevations in pulmonary capillary wedge pressure with leg elevation or exercise despite normal resting wedge pressure.
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Association of Arterial Function With Exercise Capacity in HF
Arterial and ventricular stiffness increase in parallel with advancing age and particularly in hypertensive heart disease and HFpEF. 38, 39 Arterial stiffness was inversely associated with exercise capacity in healthy adults. 40 Arterial stiffness and blunted reduction in Ea or systemic vascular resistance with exercise (impaired vascular reserve) were associated with severity of exercise intolerance in HFpEF. 6, 9, 33, 41 In RELAX, Ea (a combined index of pulsatile and resistive load) had a significant negative correlation with exercise tolerance (pVO 2 ) after adjustment for pertinent covariates. This association was driven by the pulsatile (aortic compliance) rather than the resistive component of Ea (SVR). Aortic distensibility measured by CMR is another (inverse) index of arterial stiffening and was directly correlated with pVO 2 in a study of HFpEF patients and healthy controls. 4 In RELAX, where associations were tested only in subjects with HFpEF, aortic distensibility was not associated with pVO 2 . Measures of vascular reserve were not assessed in RELAX. Measures of arterial stiffness were lower in senior athletes than age-matched healthy but sedentary controls suggesting that exercise may prevent or reverse arterial stiffening. 40 However, a trial of exercise training in HFpEF showed that training improved exercise capacity without improving arterial stiffness.
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Comorbid Conditions and Exercise Capacity in HFpEF
This study confirms that noncardiovascular (obesity and anemia) and cardiovascular (chronotropic incompetence) comorbidities are potently associated with impaired exercise tolerance in HFpEF. Each of these conditions is potentially modifiable and may represent therapeutic targets in HFpEF. 42 Obesity is common in HFpEF and is paradoxically associated with better survival except at extreme levels of obesity. 43 Obesity is associated with mobility limitation in the general population, 44 where intentional weight loss was associated with improvement in mobility. 45 Guidelines specify indexing pVO 2 to total body mass (weight) for prognostic and diagnostic use. Weight-indexed pVO 2 is inversely related to BMI, whereas nonindexed pVO 2 increases with BMI in healthy persons. Cardiovascular capacity is best reflected by pVO 2 indexed to lean body mass or expressed as a % of appropriately predicted pVO 2 (accounting for the training effect of Regression coefficients with 95% confidence intervals are shown. Figure 2 . Correlations between BMI and % predicted peak VO 2 in men and women.
obesity), whereas work capacity is related to ambulatory activity and best expressed as peak VO 2 indexed to body weight. 46 Indeed, HFpEF patients have lower weight-indexed and lean body mass-indexed pVO 2 than controls, confirming reduction in both cardiovascular and work capacity in HFpEF. 12 Here, peak VO 2 was only 67% of that predicted by the Wasserman equation, confirming reduced cardiovascular capacity in the RELAX HFpEF cohort. Although patients with lower weight-indexed VO 2 were more obese, they also had lower % predicted peak VO 2 and % predicted peak VO 2 was not related to BMI, suggesting that reduced cardiovascular capacity in HFpEF is not merely related to obesity. Although cardiovascular capacity (% predicted VO 2 ) did not correlate with BMI, the inverse relationship between work capacity (pVO 2 /kg) and BMI lends support to investigating the impact of weight reduction on functional status in HFpEF. Unfortunately, no assessment of lean body mass or peripheral muscle strength was obtained in RELAX, and thus we cannot comment on whether HFpEF patients had sarcopenic obesity contributing to their exercise intolerance. 11, 12 As oxygen-carrying capacity is strongly correlated with exercise capacity, treatment of anemia with erythropoietin has been studied in HFrEF and HFpEF with no benefit based on 6 minute walk tests. However, in a subgroup of patients that was able to complete a CPXT, those randomized to Epoetin Alfa had significant improvement in pVO 2 compared with placebo. Although these findings are inconclusive, treatment of anemia may be of benefit in some HFpEF patients. 47 The impact of treatment of chronotropic incompetence by withdrawal of negative chronotropic agents and rate adaptive pacing has not yet been characterized in HFpEF.
Additional Factors Associated With Exercise Intolerance in HFpEF
The contribution of skeletal muscle properties and oxygen extraction to variance in pVO 2 was not addressed in this LV diastolic dimension, LV mass, stroke volume, e′, SAC and mitral deceleration time were positively associated with pVO 2 , whereas mitral E/e′ ratio, Ea and NT-proBNP were negatively associated with pVO 2 . cESS indicates circumferential endocardial systolic wall stress; Ea, arterial elastance; eFS, endocardial fractional shortening; LA, left atrial; LV, left ventricle; mFS, midwall fiber shortening, PASP, pulmonary artery systolic pressure; SAC, systemic arterial compliance; and SVR, systemic vascular resistance.
analysis. Studies have varied as to whether oxygen extraction is altered in HFpEF with studies showing normal to enhanced 8, 32 or reduced 48, 49 extraction with exercise in HFpEF. Deconditioning impairs pVO 2 , whereas exercise training improved exercise capacity in small studies in HFpEF. 50 
Limitations
Because of the cross-sectional nature of the study, we cannot prove that factors associated with lower peak VO 2 are causally related to exercise intolerance. The lack of an association of most resting indices with exercise capacity in RELAX may have been influenced by the entry criteria which restricted entry to those with severe exercise intolerance and resulted in a narrower range of pVO 2 . Measures of ventricular and vascular function were assessed noninvasively, and brachial blood pressure was used as surrogate for central arterial pressure. We have not measured ventricular-vascular function during exercise; therefore; we cannot determine the influence of these measures on exercise capacity. The insignificant association between the Minnesota Living with Heart Failure Questionnaire and peak VO 2 may indicate a limitation of diseasespecific questionnaires; incorporation of nondisease-specific questionnaires such as the short form health survey (SF-36) may overcome this limitation.
Conclusion
In this well-characterized HFpEF cohort, in addition to age and sex, several potentially modifiable factors (obesity, anemia, and chronotropic incompetence) are strongly associated with the severity of exercise intolerance in HFpEF. The relatively weak or absent association of resting measures of LV systolic, LV diastolic, or vascular function with exercise capacity suggests that cardiovascular response to exercise is poorly correlated with resting measures in HFpEF.
